Virus Or Bacteriophage Patents (Class 424/93.6)
-
Publication number: 20110117060Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: ApplicationFiled: July 20, 2010Publication date: May 19, 2011Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Michael S. Roberts
-
Publication number: 20110110896Abstract: The present invention relates to methods of using RNA-binding protein modulating agents to treat of cancer, particularly patients that are susceptible to or diagnosed with estrogen receptor-negative breast cancer, such as methods of inhibiting the growth or metastasis of cancer cells comprising contacting cells with a therapeutically-effective amount of an HuR-modulating agent. The invention also relates to compositions comprising therapeutically-effective amounts of an HuR-modulating agent.Type: ApplicationFiled: October 8, 2010Publication date: May 12, 2011Applicant: The Curators of the University of MissouriInventors: Ulus Atasoy, Matthew Michael Gubin, Robert Calaluce
-
Patent number: 7939085Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.Type: GrantFiled: February 28, 2008Date of Patent: May 10, 2011Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr
-
Publication number: 20110104130Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.Type: ApplicationFiled: March 20, 2009Publication date: May 5, 2011Applicant: UNIVERSITY HEALTH NETWORKInventors: Jeffrey A. Medin, Sean Devine
-
Publication number: 20110104120Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.Type: ApplicationFiled: April 29, 2009Publication date: May 5, 2011Inventors: Xiao Xiao, Lin Yang
-
Publication number: 20110097381Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.Type: ApplicationFiled: December 29, 2010Publication date: April 28, 2011Applicant: DEPUY MITEK, INC.Inventors: Francois Binette, Joseph J. Hammer, Krish Mukhopadhyay, Joel Rosenblatt
-
Publication number: 20110097385Abstract: A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin or other therapeutic agents.Type: ApplicationFiled: March 4, 2004Publication date: April 28, 2011Applicant: TTDC BIO L.P.Inventor: Vladimir Sabetsky
-
Publication number: 20110097389Abstract: The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.Type: ApplicationFiled: January 26, 2009Publication date: April 28, 2011Applicant: P53Inventors: Robert E. Sobol, Kerstin Menander
-
Patent number: 7931893Abstract: The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.Type: GrantFiled: June 11, 2008Date of Patent: April 26, 2011Assignee: University of Iowa Research FoundationInventors: Paul B. McCray, Jr., Beverly L. Davidson, Colleen Stein
-
Patent number: 7927811Abstract: The present invention relates to polypeptides having a brain-localizing activity, molecules comprising these polypeptides, and pharmaceutical agents that confer brain-localizing activity. The present inventors are the first to reveal amino acid motif sequences involved in brain-localizing activity. Polypeptides that comprise such motif sequences and have brain localizing activity were discovered as follows: DNAs encoding polypeptides comprising random amino acid sequences were synthesized, and incorporated into a phage library. The phage library produced was used to screen for polypeptides having brain-localized activity, which yielded such several polypeptides. These polypeptides comprised common sequences, which lead to the successful discovery of amino acid motif sequences involved in brain-localizing activity.Type: GrantFiled: August 6, 2004Date of Patent: April 19, 2011Assignee: Proteus Sciences Co., Ltd.Inventor: Makoto Sawada
-
Publication number: 20110086005Abstract: Provided herein are methods of treating a proliferative disorder in a subject comprising decreasing interstitial pressure and/or increasing vascular permeability in the subject and administering to the subject an oncolytic virus. Such methods improve oncolytic viral delivery and distribution.Type: ApplicationFiled: May 27, 2009Publication date: April 14, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Matthew C. Coffey, Bradley G. Thompson, Hardev Pandha
-
Publication number: 20110070289Abstract: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver modified messenger RNA molecules to target cells in the body. Delivering to the Beta cells in the body the modified messenger RNA needed to construction of insulin or insulin receptors will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.Type: ApplicationFiled: September 18, 2009Publication date: March 24, 2011Inventors: LANE BERNARD SCHEIBER, II, LANE BERNARD SCHEIBER
-
Publication number: 20110070200Abstract: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.Type: ApplicationFiled: May 27, 2009Publication date: March 24, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Matthew C. Coffey, Bradley G. Thompson, Hardev Pandha
-
Publication number: 20110070199Abstract: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules along with messenger RNA molecules to target cells in the body. Delivering to the Beta cells in the body the ribosomal RNA needed to assist ribosomes with the construction of insulin or insulin receptors along with messenger RNA will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.Type: ApplicationFiled: September 21, 2009Publication date: March 24, 2011Inventors: Lane Bernard Scheiber, II, Lane Bernard Scheiber
-
Publication number: 20110070241Abstract: The present disclosure provides methods of inhibiting an immune response to a viral vector used in gene therapy, such as adeno-associated virus (AAV), which involves co-administration of viral vector and an interfering molecule. The interfering molecule functions by either disrupting the TLR9-MyD88-type I IFN signaling pathway and/or neutralizing Type I IFNs, thereby inhibiting the immune response directed against the viral vector. The methods additionally encompass the step of re-administering the viral vector.Type: ApplicationFiled: June 30, 2010Publication date: March 24, 2011Applicant: DUKE UNIVERSITYInventor: Yiping Yang
-
Publication number: 20110070164Abstract: The present invention relates to enveloped virus particles providing a modified composition of their envelope, methods for exogenously modifying the envelope composition of an enveloped viral particle making use of compounds consisting of a hydrophilic target domain and a lipophilic membrane anchor domain, wherein the lipophilic membrane anchor domain becomes anchored into the lipid double layer of the envelope and wherein the hydrophilic target domain becomes exposed to the surrounding incubation fluid. The invention further relates to methods and means to use said modified viral vectors and to pharmaceutical compositions containing such envelope modified viral vectors.Type: ApplicationFiled: April 3, 2009Publication date: March 24, 2011Inventors: John Dangerfield, Christoph Metzner
-
Patent number: 7910093Abstract: Disclosed herein are methods for identifying cancer cells and monitoring anti-cancer therapy in the body of a mammal by systemically delivering Sindbis viral vectors. The vector can specifically target and identify tumor cells in mice growing subcutaneously, intraperitoneally, intrapancreatically, or in the lungs. These findings demonstrate the remarkable specificity of the Sindbis vector system that is relatively safe and can specifically target tumor cells throughout the body via the bloodstream.Type: GrantFiled: August 16, 2004Date of Patent: March 22, 2011Assignee: New York UniversityInventors: Daniel Meruelo, Jen-Chieh Tseng
-
Publication number: 20110064764Abstract: The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicant: Thomas Jefferson UniversityInventors: Milosz Faber, Bernhard Dietzschold, Douglas Craig Hooper
-
Publication number: 20110064650Abstract: Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of neoplastic cells prior to administration of the cellular composition for therapy. Diagnostic methods for monitoring treatment also are provided.Type: ApplicationFiled: May 15, 2009Publication date: March 17, 2011Inventor: Aladar A. Szalay
-
Publication number: 20110064699Abstract: The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.Type: ApplicationFiled: March 10, 2009Publication date: March 17, 2011Applicant: GangaGen, Inc.Inventors: C.B. Appaiah, Jayashella Manur, Bharathi Sriram
-
Patent number: 7906312Abstract: The present invention relates to conditionally replicating viruses or pairs of viruses containing a gene switch that is activatable by transient heat or other proteotoxic stress in the presence or absence of a small molecule regulator. The gene switch controls the expression of a gene for a protein required for efficient viral replication and may also control the activity of a passenger gene.Type: GrantFiled: June 9, 2005Date of Patent: March 15, 2011Inventor: Richard Voellmy
-
Patent number: 7906113Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: GrantFiled: October 25, 2006Date of Patent: March 15, 2011Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20110059049Abstract: A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.Type: ApplicationFiled: November 17, 2008Publication date: March 10, 2011Inventors: Philippe Erbs, Johann Foloppe
-
Publication number: 20110052540Abstract: The present invention is a composition comprising a virus, a polyol and a zwitteronic compound. The present invention is also an assay for viral aggregation, which comprises analysing the size of the viral particles in a sample, wherein the particles are in admixture with a polyol, and determining from the size whether the sample contains substantially only acceptable, non-aggregated particles.Type: ApplicationFiled: August 11, 2008Publication date: March 3, 2011Inventors: Robert Shaw, Minna Nokelainen, Tuomas Mantyla, Seppo Yla-Herttuala
-
Publication number: 20110052543Abstract: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.Type: ApplicationFiled: September 3, 2010Publication date: March 3, 2011Applicant: CJ CHEILJEDANG CORPORATIONInventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
-
Publication number: 20110052541Abstract: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.Type: ApplicationFiled: September 3, 2010Publication date: March 3, 2011Applicant: CJ CHEILJEDANG CORPORATIONInventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
-
Publication number: 20110052539Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.Type: ApplicationFiled: September 17, 2007Publication date: March 3, 2011Inventors: David Stojdl, Christopher Brown, John Bell
-
Publication number: 20110052542Abstract: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.Type: ApplicationFiled: September 3, 2010Publication date: March 3, 2011Applicant: CJ CHEILJEDANG CORPORATIONInventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
-
Publication number: 20110052544Abstract: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.Type: ApplicationFiled: September 3, 2010Publication date: March 3, 2011Applicant: CJ CHEILJEDANG CORPORATIONInventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
-
Publication number: 20110045058Abstract: The invention described herein features methods, compositions, and kits for introducing a nucleic acid molecule or biologically active molecule into a eukaryotic cell in vitro or in vivo utilizing a reagent containing energy-rich additives.Type: ApplicationFiled: November 20, 2008Publication date: February 24, 2011Applicant: Beth Israel Deaconess Medical CenterInventor: Anny Usheva-Simidjiyska
-
Publication number: 20110044952Abstract: The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection.Type: ApplicationFiled: November 26, 2008Publication date: February 24, 2011Applicant: Ottawa Health Research InstituteInventors: John Cameron Bell, John Hiscott, Hesham Abdelbary, Thi Lien-Anh Nguyen, Jean-Simon Diallo
-
Publication number: 20110044937Abstract: The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response.Type: ApplicationFiled: July 27, 2007Publication date: February 24, 2011Applicant: OTTAWA HEALTH RESEARCH INSTITUTEInventors: John C. Bell, Caroline Judith Breitbach, Harry Atkins
-
Publication number: 20110047631Abstract: The invention provides non-human transgenic animals as models of neurodegenerative brain pathology, including, but not limited to, Alzheimer's disease (AD), and cancer. The non-human transgenic animals of the present invention include an exogenous DNA that reduces or eliminates the expression and/or function of a molecular chaperone, including, but not limited to heat shock protein 110 (Hsp1 10) or heat shock protein 70 (Hsp70). These non-human transgenic animals may be used in methods of screening and identifying compounds useful for the prevention and/or treatment of neurodegenerative brain pathology and/or cancer.Type: ApplicationFiled: January 8, 2010Publication date: February 24, 2011Inventors: Nahid F. Mivechi, Binnur Eroglu, Dimitrios Moskofidis
-
Patent number: 7892533Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: GrantFiled: October 28, 2009Date of Patent: February 22, 2011Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20110038840Abstract: The present invention provides a disinfectant composition including a phage of Acinetobacter baumannii and a carrier. The present invention also provides a method for disinfecting a medical institute or a medical research institute, including the steps of applying an effective amount of a phage of Acinetobacter baumannii to the medical institute or the medical research institute for reducing amount of Acinetobacter baumannii in the medical institute or the medical research institute.Type: ApplicationFiled: August 11, 2010Publication date: February 17, 2011Applicant: TZU CHI BUDDHIST GENERAL HOSPITALInventors: Li-Kuang Chen, Nien-Tsung Lin
-
Publication number: 20110033424Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.Type: ApplicationFiled: April 28, 2010Publication date: February 10, 2011Inventor: Per Sonne Holm
-
Publication number: 20110033425Abstract: A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.Type: ApplicationFiled: December 19, 2008Publication date: February 10, 2011Applicant: Deutsches KrebsforschungszentrumInventors: Zahari Raykov, Jean Rommelaere, Nathalia Giese, Marc Aprahamian
-
Publication number: 20110027310Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer and prostate cancer.Type: ApplicationFiled: May 5, 2008Publication date: February 3, 2011Inventors: Jeffrey A. Medin, Andrea McCart, Severine Loisel-Meyer
-
Patent number: 7879336Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.Type: GrantFiled: June 23, 2008Date of Patent: February 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Shelly L. Shields, Hans A Draayer, Michael J Huether
-
Publication number: 20110020289Abstract: The present invention provides a novel mycovirus that suppresses phytopathogenic fungi and a novel method for controlling plant diseases. A novel mycovirus that is present endogenously in a predetermined rice blast fungus, has four types of double-stranded RNAs of 2.8 to 3.6 kb, and suppresses a phytopathogenic fungus has been found. This virus suppresses phytopathogenic fungi such as rice blast fungus.Type: ApplicationFiled: January 5, 2009Publication date: January 27, 2011Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGYInventors: Hiromitsu Moriyama, Toshiyuki Fukuhara, Tsutomu Arie, Tohru Teraoka
-
Publication number: 20110020287Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.Type: ApplicationFiled: December 23, 2008Publication date: January 27, 2011Inventors: Jean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamiam
-
Publication number: 20110020288Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.Type: ApplicationFiled: August 2, 2010Publication date: January 27, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventor: Matthew C. Coffey
-
Publication number: 20110020290Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.Type: ApplicationFiled: October 4, 2010Publication date: January 27, 2011Inventors: James Soothill, Catherine Hawkins, David Harper
-
Patent number: 7875446Abstract: A process is described for purifying vesicular stomatitis virus (VSV) from cell culture fluid of a mammalian cell culture infected with VSV, the process comprising: clarifying the cell culture fluid by low-speed centrifugation and recovering the VSV in the supernatant; filtering the supernatant through a 0.2 to 0.45 ?m filter and recovering the VSV in the filtered solution; loading the VSV filtered solution onto a anion exchange membrane adsorber equilibrated with a first pH buffered salt solution, eluting the VSV from the anion exchange membrane adsorber with a second pH buffered salt solution and recovering the eluted VSV fractions; purifying the recovered VSV by tangential flow filtration (TFF) using a TFF membrane having a molecular weight cutoff between 300 kDa and 1,000 kDa and recovering the VSV in the retentate, and filtering the VSV retentate through a 0.2 to 0.22 ?m filter and recovering the VSV in the filtered solution.Type: GrantFiled: April 19, 2007Date of Patent: January 25, 2011Assignee: Wyeth LLCInventors: Yun Kang, Mark William Cutler, Amadou Affrey Ouattara, Kristen Elissa Syvertsen
-
Publication number: 20110014275Abstract: This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPAR?, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPAR?, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.Type: ApplicationFiled: August 30, 2010Publication date: January 20, 2011Applicant: Saint Louis UniversityInventor: Dechun Li
-
Publication number: 20110014157Abstract: The invention relates to a method for producing a mixture of bacteriophages, wherein at least two different bacteriophage strains have been reproduced separately, wherein a staphylococcus strain is grown in an preculture with each of strains of a bacteriophage that can lyse staphylococci and is then further reproduced in a main culture, and is then purified, and the different strains are then mixed, wherein the mixture of bacteriophages used comprises at least two different serotypes of bacteriophages that lyse specifically bacteria of the species Staphylococcus.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Applicant: PHYTOLINE GMBHInventor: Robert F. Müller
-
Publication number: 20110014228Abstract: The present invention relates to recombinant replicable viral vectors and viruses which are modified with IL23. This IL23 modified virus is highly immunogenic and attenuated for neurotropic pathology found in the wild type viruses. These viruses and vectors can be used for treatment of a variety of cancers and for vaccination against many viral, bacterial, or parasitic diseases.Type: ApplicationFiled: June 15, 2010Publication date: January 20, 2011Applicant: NEW YORK UNIVERSITYInventors: Carol Shoshkes REISS, James M. MILLER
-
Publication number: 20110014155Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: July 22, 2010Publication date: January 20, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7871626Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: GrantFiled: July 27, 2006Date of Patent: January 18, 2011Assignee: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Publication number: 20110008293Abstract: The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.Type: ApplicationFiled: November 14, 2008Publication date: January 13, 2011Applicant: THE UNIVERSITY OF QUEENSLANDInventor: Bhesh Bhandari